An interventional study of Modified Diprobase formulation (BAY987534) in Atopic Dermatitis, sponsored by Bayer. Completed at 1 site in United Kingdom. Open to participants aged 6 Months to 48 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-24.
Sponsored by Bayer · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Dermatitis, Atopic by Bayer — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · Bayer.
Among the 14 studies in Dermatitis, Atopic by Bayer, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 with no phase, and was the 11th registered.
1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.
Browse Dermatitis, Atopic studies →None of the 14 studies in Dermatitis, Atopic by Bayer is open now. The open studies under Dermatitis, Atopic, anywhere →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 6 Months to 48 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 42 across the 13 interventional studies, 300 across the 1 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Dermatitis, Atopic by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the safety and tolerability of the modified Diprobase formulation over 14 days in infants and children with a history of Atopic Dermatitis (AD).
Infants and children with quiescent atopic dermatitis
Device: Modified Diprobase formulation (BAY987534)
The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.
Number of participants with adverse event (AE)
Time frame: Up to 14 days
Severity of adverse event
The intensity of an AE is classified according to the following categories: * Mild * Moderate * Severe
Time frame: Up to 14 days
Ran from Sep 2018 to primary completion in Aug 2019, 10 months.
Of 69 industry-sponsored interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 10 months is above that.
Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.